Your browser doesn't support javascript.
loading
The epidemiology and societal costs of myasthenia gravis in Norway: A non-interventional study using national registry data.
Engebretsen, Ingrid; Gilhus, Nils Erik; Kristiansen, Ivar Sønbø; Sæther, Erik Magnus; Lindberg-Schager, Ingrid; Arneberg, Fredrik; Bugge, Christoffer.
Afiliação
  • Engebretsen I; Oslo Economics, Oslo, Norway.
  • Gilhus NE; Department of Clinical Medicine, University of Bergen, Bergen, Norway.
  • Kristiansen IS; Department of Neurology, Haukeland University Hospital, Bergen, Norway.
  • Sæther EM; Oslo Economics, Oslo, Norway.
  • Lindberg-Schager I; Department of Health Management and Health Economics, Institute of Health and Society, University of Oslo, Oslo, Norway.
  • Arneberg F; Department of Public Health, Research Unit for General Practice, University of Southern Denmark, Odense M, Denmark.
  • Bugge C; Oslo Economics, Oslo, Norway.
Eur J Neurol ; 31(5): e16233, 2024 May.
Article em En | MEDLINE | ID: mdl-38323756
ABSTRACT
BACKGROUND AND

PURPOSE:

With the emergence of new treatment options for myasthenia gravis (MG), there is a need for information regarding epidemiology, healthcare utilization, and societal costs to support economic evaluation and identify eligible patients. We aimed to enhance the understanding of these factors using nationwide systematic registry data in Norway.

METHODS:

We received comprehensive national registry data from five Norwegian health- and work-related registries. The annual incidence and prevalence were estimated for the period 2013-2021 using nationwide hospital and prescription data. The direct, indirect (productivity losses) and intangible costs (value of lost life-years [LLY] and health-related quality of life [HRQoL]) related to MG were estimated over a period of 1 year.

RESULTS:

In 2021, the incidence of MG ranged from 15 to 16 cases per year per million population depending on the registry used, while the prevalence varied between 208.9 and 210.3 per million population. The total annual societal costs of MG amounted to EUR 24,743 per patient, of which EUR 3592 (14.5%) were direct costs, EUR 8666 (35.0%) were productivity loss, and EUR 12,485 (50.5%) were lost value from LLY and reduced HRQoL.

CONCLUSION:

The incidence and prevalence of MG are higher than previously estimated, and the total societal costs of MG are substantial. Our findings demonstrate that productivity losses, and the value of LLY and HRQoL constitute a considerable proportion of the total societal costs.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Custos de Cuidados de Saúde / Miastenia Gravis Tipo de estudo: Health_economic_evaluation / Screening_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Eur J Neurol Assunto da revista: NEUROLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Noruega

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Custos de Cuidados de Saúde / Miastenia Gravis Tipo de estudo: Health_economic_evaluation / Screening_studies Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Eur J Neurol Assunto da revista: NEUROLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Noruega